Processa Pharmaceuticals (PCSA) Net Equity Issued and Repurchased (2014 - 2026)

Processa Pharmaceuticals (PCSA) has 7 years of Net Equity Issued and Repurchased data on file, last reported at $245103.0 in Q1 2026.

• Quarterly Net Equity Issued and Repurchased fell 94.48% year-over-year to $245103.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.4 million (up 110.18% YoY) and the FY2025 annual result came in at $16.6 million, up 113.8% from the prior year.
• Net Equity Issued and Repurchased eased to $245103.0 in Q1 2026, from $3.0 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $6.4 million in Q1 2023 to a low of -$30607.0 in Q4 2023.
• A 4-year average of $2.8 million and a median of $2.9 million in 2025 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2025 — Net Equity Issued and Repurchased soared 36071.72% — and 2026, when it plunged 94.48%.
• Tracing PCSA's Net Equity Issued and Repurchased over 4 years: stood at -$30607.0 in 2023, then soared by 1894.88% to $549358.0 in 2024, then jumped by 442.29% to $3.0 million in 2025, then plunged by 91.77% to $245103.0 in 2026.
• The last three Net Equity Issued and Repurchased figures came in at $245103.0 (Q1 2026), $3.0 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.